Late-Breaking Oral Presentation Intravenous delivery of VY1706, a CNS penetrant AAV gene therapy for Alzheimer’s disease, ...

Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -WALTHAM, Mass., ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Defense Secretary Pete Hegseth has become the clearest subject of such angst, with his neatly groomed hair, dark blue suits, ...

The JBL Summit Ama is a hugely capable standmounter that’s a truly entertaining listen.

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous ...

A new book charts the creation of a secretive system that automates warfare for the military. The progression from target ...

Telehealth doesn't suit everybody, but the results from two key ASX-listed operators show the remote medium is gaining ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient popu ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...